Zhu Xingmiao, Hu Hao, Yao Dongning
Department of Drug Regulatory Science and Pharmacoeconomics, School of Pharmacy, Nanjing Medical University, Nanjing, China.
State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China.
Int J Clin Pharm. 2025 Jun 28. doi: 10.1007/s11096-025-01957-5.
To improve access to innovative medications, the Chinese government introduced a dual-channel policy, allowing community pharmacies to dispense innovative drugs listed in the National Reimbursement Drug List of the national healthcare security system. However, research on how community pharmacies interpret and respond to these policies remains limited.
To investigate community pharmacy manager/ pharmacist perceptions of and responses to the dual-channel policy, with a focus on improving accessibility and the rational use of innovative drugs for patients in China.
A qualitative research design, involving semi-structured interviews, was conducted in Jiangsu Province, China. The interview guide was developed to address key domains relevant to community and licensed pharmacists. The participants were recruited through purposive and snowball sampling to ensure diverse perspectives. The interviews were audio-recorded, transcribed, and analyzed using the framework method. NVivo software was used for coding and theme development, until theoretical saturation was achieved.
The participants viewed the dual-channel policy as an opportunity to expand business operations and enhance market competitiveness. However, they also identified several challenges, including space and storage constraints, regional inconsistencies in electronic prescription systems, limited influence on hospital prescription flows, selective partnerships with pharmaceutical companies, and elevated service expectations from patients. In response, pharmacies have implemented a range of hardware-focused strategies, such as upgrading service areas, integrating insurance billing systems, and developing patient management platforms, as well as soft competence strategies, including pharmacist training on innovative drugs and disease knowledge, interpretation of reimbursement policies, and emergency response preparedness.
This study demonstrates that participation in a dual-channel policy is widely perceived by community pharmacies as a strategic opportunity, despite the associated operational and systemic challenges. Proactive engagement with the policy not only strengthened their competitive positioning but also contributed to improved pharmaceutical services and patient care outcomes.
为了改善创新药物的可及性,中国政府出台了双通道政策,允许社区药店调配国家医疗保障体系《国家医保药品目录》中列出的创新药物。然而,关于社区药店如何解读和应对这些政策的研究仍然有限。
调查社区药店经理/药剂师对双通道政策的看法和应对措施,重点是提高中国患者获得创新药物的可及性并促进其合理使用。
在中国江苏省进行了一项定性研究,采用半结构化访谈。访谈指南围绕与社区和执业药师相关的关键领域制定。通过目的抽样和滚雪球抽样招募参与者,以确保观点的多样性。访谈进行录音、转录,并使用框架法进行分析。使用NVivo软件进行编码和主题开发,直至达到理论饱和。
参与者将双通道政策视为扩大业务运营和增强市场竞争力的机会。然而,他们也指出了一些挑战,包括空间和存储限制、电子处方系统的地区差异、对医院处方流的影响有限、与制药公司选择性合作以及患者对服务期望的提高。作为回应,药店实施了一系列以硬件为重点的策略,如升级服务区域、整合医保计费系统和开发患者管理平台,以及软能力策略,包括对药剂师进行创新药物和疾病知识培训、报销政策解读以及应急准备。
本研究表明,尽管存在相关的运营和系统挑战,但社区药店普遍认为参与双通道政策是一个战略机遇。积极参与该政策不仅增强了他们的竞争地位,还有助于改善药学服务和患者护理结果。